REFERENCES
1. Society AC. Cancer Treatment & Survivorship Facts & Figures
2016-2017. 2017.
2. Haggar FA, Pereira G, Preen D, Holman CD, Einarsdottir K. Adverse
obstetric and perinatal outcomes following treatment of adolescent and
young adult cancer: a population-based cohort study. PLoS One.2014;9(12):e113292.
3. van der Kooi ALF, Brewster DH, Wood R, et al. Perinatal risks in
female cancer survivors: A population-based analysis. PLoS One.2018;13(8):e0202805.
4. Anderson C, Engel SM, Mersereau JE, et al. Birth Outcomes Among
Adolescent and Young Adult Cancer Survivors. JAMA Oncol.2017;3(8):1078-1084.
5. Gorman JR, Bailey S, Pierce JP, Su HI. How do you feel about
fertility and parenthood? The voices of young female cancer survivors.J Cancer Surviv. 2012;6(2):200-209.
6. Gorman JR, Malcarne V, Pierce JP, Su HI. A multidimensional scale to
measure the reproductive concerns of young adult cancer survivors.Journal of Cancer Survivorship. 2013.
7. Gorman JR, Su HI, Pierce JP, Roberts SC, Dominick SA, Malcarne VL. A
multidimensional scale to measure the reproductive concerns of young
adult female cancer survivors. J Cancer Surviv.2014;8(2):218-228.
8. van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, Laven JSE,
Wallace WHB, Anderson RA. Perinatal complications in female survivors of
cancer: a systematic review and meta-analysis. Eur J Cancer.2019;111:126-137.
9. Kao WH, Kuo CF, Chiou MJ, et al. Adverse birth outcomes in adolescent
and young adult female cancer survivors: a nationwide population-based
study. Br J Cancer. 2020;122(6):918-924.
10. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and
causes of preterm birth. Lancet. 2008;371(9606):75-84.
11. Farland LV, Stern JE, Hwang SS, et al. Early-life cancer,
infertility, and risk of adverse pregnancy outcomes: a registry linkage
study in Massachusetts. Cancer Causes Control.2021;32(2):169-180.
12. American College of O, Gynecologists, the Society for Maternal-Fetal
M, Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and
review. Am J Obstet Gynecol. 2016;215(3):B17-22.
13. Rivara FP, Fihn SD. Severe Maternal Morbidity and Mortality: JAMA
Network Open Call for Papers. JAMA Netw Open. 2020;3(1):e200045.
14. Chao C, Xu L, Bhatia S, et al. Cardiovascular Disease Risk Profiles
in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser
Permanente AYA Cancer Survivors Study. J Clin Oncol.2016;34(14):1626-1633.
15. Ethics Committee of the American Society for Reproductive Medicine.
Electronic address Aao. Fertility preservation and reproduction in
patients facing gonadotoxic therapies: an Ethics Committee opinion.Fertil Steril. 2018;110(3):380-386.
16. Technology SfAR. sart.org. Accessed.
17. Dunietz GL, Holzman C, McKane P, et al. Assisted reproductive
technology and the risk of preterm birth among primiparas. Fertil
Steril. 2015;103(4):974-979 e971.
18. Belanoff C, Declercq ER, Diop H, et al. Severe Maternal Morbidity
and the Use of Assisted Reproductive Technology in Massachusetts.Obstet Gynecol. 2016;127(3):527-534.
19. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs:
building a novel node in the learning health care system. Health
Aff (Millwood). 2014;33(7):1187-1194.
20. Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring
pregnancy episodes and outcomes within a network of observational
databases. PLoS One. 2018;13(2):e0192033.
21. Hornbrook MC, Whitlock EP, Berg CJ, et al. Development of an
algorithm to identify pregnancy episodes in an integrated health care
delivery system. Health Serv Res. 2007;42(2):908-927.
22. Bandoli G, Chambers CD, Wells A, Palmsten K. Prenatal Antidepressant
Use and Risk of Adverse Neonatal Outcomes. Pediatrics.2020;146(1).
23. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR,
Hernandez-Diaz S. Algorithms to estimate the beginning of pregnancy in
administrative databases. Pharmacoepidemiol Drug Saf.2013;22(1):16-24.
24. Li Q, Andrade SE, Cooper WO, et al. Validation of an algorithm to
estimate gestational age in electronic health plan databases.Pharmacoepidemiol Drug Saf. 2013;22(5):524-532.
25. Nina Veeravalli ST, Gretchen Bandoli. Family Ties: Linking Mothers
and Newborns in a Large, De-Identified Claims Database. AcademyHealth
Annual Research Meeting; 2019; Washington, D.C.
26. Institute NC. Surveillance, Epidemiology, and End Results (SEER).
In.
27. Abraha I, Montedori A, Serraino D, et al. Accuracy of administrative
databases in detecting primary breast cancer diagnoses: a systematic
review. BMJ Open. 2018;8(7):e019264.
28. Lemos EV, Zhang D, Van Voorhis BJ, Hu XH. Healthcare expenses
associated with multiple vs singleton pregnancies in the United States.Am J Obstet Gynecol. 2013;209(6):586 e581-586 e511.
29. Martin AS, Monsour M, Kissin DM, Jamieson DJ, Callaghan WM, Boulet
SL. Trends in Severe Maternal Morbidity After Assisted Reproductive
Technology in the United States, 2008-2012. Obstet Gynecol.2016;127(1):59-66.
30. Bateman BT, Mhyre JM, Ehrenfeld J, et al. The risk and outcomes of
epidural hematomas after perioperative and obstetric epidural
catheterization: a report from the Multicenter Perioperative Outcomes
Group Research Consortium. Anesth Analg. 2013;116(6):1380-1385.
31. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a
comorbidity index for use in obstetric patients. Obstet Gynecol.2013;122(5):957-965.
32. Division of Reproductive Health NCfCDPaHP. How Does CDC
Identify Severe Maternal Morbidity? : CDC;2019.
33. Luke B, Brown MB. Contemporary risks of maternal morbidity and
adverse outcomes with increasing maternal age and plurality.Fertil Steril. 2007;88(2):283-293.
34. VanderWeele TJ. A unification of mediation and interaction: a 4-way
decomposition. Epidemiology. 2014;25(5):749-761.
35. Valente MJ, Rijnhart JJM, Smyth HL, Muniz FB, MacKinnon DP. Causal
Mediation Programs in R, Mplus, SAS, SPSS, and Stata. Struct Equ
Modeling. 2020;27(6):975-984.
36. Tang M, Webber K. Fertility and pregnancy in cancer survivors.Obstet Med. 2018;11(3):110-115.
37. D’Alton ME, Bonanno CA, Berkowitz RL, et al. Putting the ”M” back in
maternal-fetal medicine. Am J Obstet Gynecol.2013;208(6):442-448.
38. Bombard JM, Robbins CL, Dietz PM, Valderrama AL. Preconception care:
the perfect opportunity for health care providers to advise lifestyle
changes for hypertensive women. Am J Health Promot. 2013;27(3
Suppl):S43-49.
39. Wiles KS, Bramham K, Vais A, et al. Pre-pregnancy counselling for
women with chronic kidney disease: a retrospective analysis of nine
years’ experience. BMC Nephrol. 2015;16:28.
40. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in
Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med.2017;377(7):613-622.
41. Alina Zgardau PCN, Sumit Gupta, Joel G. Ray, Nancy N. Baxter,
Chenthila Nagamuthu, Cindy Lau, Alison Park. Obstetrical and perinatal
complications in survivors of childhood, adolescent, and young adult
cancer: A population-based study. Journal of Clinical Oncology.2020;38:10529.
42. Fingar KR, Hambrick MM, Heslin KC, Moore JE. Trends and Disparities
in Delivery Hospitalizations Involving Severe Maternal Morbidity,
2006-2015: Statistical Brief #243. In: Healthcare Cost and
Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006.
43. Practice Committee of the American Society for Reproductive
Medicine. Electronic address Aao, Practice Committee of the Society for
Assisted Reproductive T. Guidance on the limits to the number of embryos
to transfer: a committee opinion. Fertil Steril.2017;107(4):901-903.
44. Norwitz ER, Edusa V, Park JS. Maternal physiology and complications
of multiple pregnancy. Semin Perinatol. 2005;29(5):338-348.
45. Metcalfe A, Lix LM, Johnson JA, et al. Validation of an obstetric
comorbidity index in an external population. BJOG.2015;122(13):1748-1755.
46. Virnig BA, McBean M. Administrative data for public health
surveillance and planning. Annu Rev Public Health.2001;22:213-230.
47. Clapp MA, James KE, Kaimal AJ, Sommers BD, Daw JR. Association of
Medicaid Expansion With Coverage and Access to Care for Pregnant Women.Obstet Gynecol. 2019;134(5):1066-1074.
48. Lund JL, Sturmer T, Harlan LC, et al. Identifying specific
chemotherapeutic agents in Medicare data: a validation study. Med
Care. 2013;51(5):e27-34.
49. Lamont EB, Lan L. Sensitivity of Medicare claims data for measuring
use of standard multiagent chemotherapy regimens. Med Care.2014;52(3):e15-20.
50. Zhou B, Kwan B, Desai MJ, et al. Long-term antimullerian hormone
patterns differ by cancer treatment exposures in young breast cancer
survivors. Fertil Steril. 2022.